BioWa, Inc. has announced that it has entered into a second agreement with MedImmune to provide additional access to BioWa's patented POTELLIGENT® Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.
The agreement grants to MedImmune non-exclusive license rights to develop, manufacture and market antibodies based on POTELLIGENT® Technology for an undisclosed number of targets. In return, BioWa receives from MedImmune certain fees and milestone payments during product development, as well as royalties on marketed products using ADCC enhanced antibodies.
"We are pleased to extend our relationship with MedImmune, a world-leading biologics business and the cornerstone to AstraZeneca's plans to establish a major international presence in the research and development of biological therapeutics," said Dr. Masamichi Koike, President and CEO of BioWa. "With MedImmune's superior expertise in antibody-based drug development, this collaboration complements BioWa's mission to bring about the benefit of POTELLIGENT® Technology to patients as quickly as possible."